In this study, Nightingale’s blood biomarker analysis service was used to quantify 228 lipid and metabolite measures for 5,359 participants in the PROSPER trial at 6-months post-randomization and 72,185 individuals across eight population cohorts.
This study is pioneering for combing large randomized trial data with Mendelian randomization analyses (using genetic variants as naturally-occurring trials). Findings provide evidence that PCSK9 inhibition results in subtly different metabolic alterations than those resulting from statin medications. Incorporating analyses of the full metabolite from the large INTERVAL trial and other cohort studies also demonstrates the benefits of comprehensively metabolic profiling large cohorts and biobanks.
Our latest health headlines delivered to your inbox.